Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MTIG7192A (anti-TIGIT) plus atezolizumab in first-line advanced NSCLC
2018-000280-81Phase 2Active
- Sponsor
- Roche
- Start
- May 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MTIG7192A + atezolizumab with Placebo + atezolizumab (2 arms). Primary endpoint: Objective response rate. Started May 2018; status: active.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-000280-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000280-81.